Show simple item record

dc.contributor.authorMorris, Craig C
dc.contributor.authorStroud, Steven C
dc.contributor.authorGolconda, Umamaheshwari
dc.contributor.authorGregoire, Sharon A
dc.contributor.authorJuneman, Elizabeth B
dc.date.accessioned2021-04-09T22:45:27Z
dc.date.available2021-04-09T22:45:27Z
dc.date.issued2020-05-14
dc.identifier.citationMorris, C. C., Stroud, S. C., Golconda, U., Gregoire, S. A., & Juneman, E. B. (2020). Orthotopic Heart Transplant Recipient with Enteric-coated Mycophenolate Sodium (Myfortic) Induced Colitis. The American journal of case reports, 21, e920235-1.en_US
dc.identifier.issn1941-5923
dc.identifier.pmid32404861
dc.identifier.doi10.12659/AJCR.920235
dc.identifier.urihttp://hdl.handle.net/10150/657706
dc.description.abstractObjective: Rare disease Background: Mycophenolic acid is an immunosuppressive drug commonly used in solid organ transplantation to prevent acute and chronic allograft rejection. There are 2 common preparations of mycophenolic acid including mycophenolate mofetil (Cellcept), and enteric-coated mycophenolate sodium (Myfortic) which was developed to reduce the high rate of gastrointestinal side effects seen with Cellcept. Cases of mycophenolate mofetil induced colitis have been described in solid organ transplant patients and rarely in heart transplant patients, but enteric-coated mycophenolate sodium induced colitis is very rare and has not been reported in heart transplant patients. Case Report: A 66-year old male with an orthotopic heart transplant was admitted with diarrhea. The patient was on an immunosuppression regimen including mycophenolate mofetil for 10 weeks post-transplantation until complaining of soft stools and bloating. At this time, he was switched to enteric-coated mycophenolate sodium. At week 11 post-transplantation, the patient was admitted to the hospital with worsening diarrhea. Extensive workup was unrevealing. Colonoscopy with biopsy showed features of mycophenolic acid induced colitis. Enteric coated mycophenolate sodium was discontinued, and the patient's diarrhea markedly improved over the next 48 hours. The patient had no signs of colitis or solid organ rejection at 7-month follow up appointment. Conclusions: Although a diagnosis of exclusion, enteric-coated mycophenolate sodium induced colitis should be considered in the differential of an orthotopic heart transplant patient with diarrhea as discontinuing the medication can improve symptoms and avoid costly workups, however, patients should be monitored closely for signs of rebound rejection.en_US
dc.language.isoenen_US
dc.publisherINT SCIENTIFIC INFORMATION, INCen_US
dc.rights© Am J Case Rep, 2020. This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectColitisen_US
dc.subjectHeart Transplantationen_US
dc.subjectMycophenolic Aciden_US
dc.titleOrthotopic Heart Transplant Recipient with Enteric-coated Mycophenolate Sodium (Myfortic) Induced Colitisen_US
dc.typeArticleen_US
dc.identifier.eissn1941-5923
dc.contributor.departmentUniv Arizona, Coll Med, Sarver Heart Ctren_US
dc.contributor.departmentUniv Arizona, Coll Med, Dept Patholen_US
dc.identifier.journalAMERICAN JOURNAL OF CASE REPORTSen_US
dc.description.noteOpen access articleen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleThe American journal of case reports
dc.source.volume21
dc.source.beginpagee920235
dc.source.endpage
refterms.dateFOA2021-04-09T22:45:28Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
920235.pdf
Size:
831.0Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

© Am J Case Rep, 2020. This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
Except where otherwise noted, this item's license is described as © Am J Case Rep, 2020. This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).